Table 1: Novel targeted agents currently under evaluation for mRCC.

AgentDescriptionTrial ID numberPhaseDesign

BrivanibDual VEGFR2 and FGFR-1NCT01253668IIRCC patients after prior treatment with TKI or bevacizumab
CrizotinibAlk and c-MET TKINCT01524926IIPatients with solid tumors
BIBF 120VEGFR 1–3 PDGFR and FGFR TKINCT01024920IIversus sunitinib in untreated mRCC patients
VEGF-TrapSoluble decoy receptor; derivative of VEGFR1 NCT00357760IIccRCC patients after at least 1 prior treatment with TKI
Ridaforolimus MTORC1 selective inhibitorNCT01169532IIn combination with vorinostat in patients with solid tumors
NCT01295632IIn combination with MK2206 or γ-secretase inhibitor MK-0752 in patients with advanced solid tumors
MK-2206AKT inhibitorNCT01239342IIVersus everolimus in refractory RCC patients
NVP-BEZ235Dual PI3K/mTOR inhibitorNCT01482156IIn combination with everolimus in patients with advanced solid tumors
GDC-0980Dual PI3K/mTOR inhibitorNCT01442090IIIn comparison with everolimus in mRCC patients progressed on VEGF-targeted therapy
AMG-386Ang-1/2 inhibitorNCT01548482IIIn combination with temsirolimus in patients with advanced solid tumors
MDX-1203Anti-CD70 Ab-drug conjugateNCT00944905IPretreated ccRCC or B-cell non-Hodgkin's lymphoma
MDX-1411Anti-CD70 Ab-drug conjugateNCT00656734IccRCC pts treated with up to 6 prior systemic therapies
SGN-75Anti-CD70 Ab-drug conjugateNCT01015911IPretreated ccRCC or B-cell non-Hodgkin's lymphoma
GirentuximabChimeric mAb cG250 NCT00087022IIIAdjuvant cG250 versus placebo in pts with ccRCC and high risk of recurrence
cG250-Lu177Lutetium-177 labeled cG250NCT00142415IIpts with advanced and progressive ccRCC
90Y-cG250Yttrium-90 labeled cG250NCT00199875Ipts with advanced and progressive ccRCC
PanitumumabAnti-EGFR mAbNCT00425035IImRCC pts naïve or after cytokine treatment
VorinostatHDAC inhibitorNCT00278395IImRCC pts naïve or after cytokine treatment
RO4929097γ-secretase/Notch inhibitorNCT01141569IIccRCC pts after anti-VEGF and/or mTOR inhibitor and/or immunotherapy failure
AS141126-mer DNA aptamerNCT00740441IIccRCC pts after at least 1 prior treatment with TKI